PALI PALISADE BIO INC revenue, earnings and financials

For the quarter ended June 30, 2026, PALISADE BIO INC reported revenue of $500K, net income of −$10.6M and diluted EPS of −$0.05; over the last four quarters revenue was $500K and net income −$31.9M; for the fiscal year ended December 2025 revenue was $0.

PALI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$18.1M, net income −$16.8M (margin n/a), EPS −$0.30
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$14.9M, net income −$14.4M (margin n/a), EPS −$10.19
• Fiscal year ended Dec 2023: revenue $250K, gross profit n/a, operating income −$13.1M, net income −$12.3M (margin -4920.0%), EPS −$27.01
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$15.7M, net income −$14.3M (margin n/a), EPS −$16.53
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$41.9M, net income −$26.6M (margin n/a), EPS −$169.74

PALI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $500K, net income −$10.6M, EPS −$0.05
• Quarter ended Mar 31, 2026: revenue $0, net income −$9.60M, EPS −$0.05
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$8.90M, EPS $1.13
• Quarter ended Sep 30, 2025: revenue $0, net income −$2.87M, EPS −$0.38
• Quarter ended Jun 30, 2025: revenue $0, net income −$2.78M, EPS −$0.58
• Quarter ended Mar 31, 2025: revenue $0, net income −$2.23M, EPS −$0.47
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$3.34M, EPS $0.04
• Quarter ended Sep 30, 2024: revenue $0, net income −$3.49M, EPS −$2.32
• Quarter ended Jun 30, 2024: revenue $0, net income −$4.08M, EPS −$3.32
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$3.53M, EPS −$4.59
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$2.97M, EPS −$3.57
• Quarter ended Sep 30, 2023: revenue $0, net income −$3.60M, EPS −$7.38
• Quarter ended Jun 30, 2023: revenue $0, net income −$3.39M, EPS −$7.93
• Quarter ended Mar 31, 2023: revenue $250K, net income −$2.34M, EPS −$8.13
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$3.72M, EPS $6.30
• Quarter ended Sep 30, 2022: revenue $0, net income −$3.99M, EPS −$4.10
• Quarter ended Jun 30, 2022: revenue $0, net income −$2.34M, EPS −$5.77
• Quarter ended Mar 31, 2022: revenue $0, net income −$4.21M, EPS −$12.96
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $1.07M, EPS −$165.27
• Quarter ended Sep 30, 2021: revenue n/a, net income $8.09M, EPS $0.42

PALI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$10.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$12.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$11.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$13.4M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$14.8M, share buybacks n/a

PALI balance sheet

• Jun 30, 2026: cash $125M, total assets $127M, total liabilities $5.57M, shareholders' equity $122M
• Mar 31, 2026: cash $133M, total assets $133M, total liabilities $5.95M, shareholders' equity $127M
• Dec 31, 2025: cash $133M, total assets $134M, total liabilities $4.96M, shareholders' equity $129M
• Sep 30, 2025: cash $5.23M, total assets $6.97M, total liabilities $3.76M, shareholders' equity $3.21M
• Jun 30, 2025: cash $5.42M, total assets $6.67M, total liabilities $4.05M, shareholders' equity $2.62M
• Mar 31, 2025: cash $7.23M, total assets $8.19M, total liabilities $2.86M, shareholders' equity $5.33M
• Dec 31, 2024: cash $9.82M, total assets $10.9M, total liabilities $3.39M, shareholders' equity $7.49M
• Sep 30, 2024: cash $8.04M, total assets $9.34M, total liabilities $2.73M, shareholders' equity $6.61M

What is PALI's revenue?

PALISADE BIO INC reported $500K of revenue over its last four quarters, through June 30, 2026.

Is PALI profitable?

No. PALISADE BIO INC lost $31.9M over the last four quarters.

What is PALI's EPS?

Diluted earnings per share over the last four quarters were $0.65; −$0.05 in the latest quarter.

PALI ownership and insider trades · All stocks